Erythromelalgia
Methodology & AI Transparency ⓘ
Erythromelalgia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Erythromelalgia uses ICD-10 I73.81 across Blood Pressure specialty care.
- 3 Typical cash cost range: Clinicians assessing Erythromelalgia focus on elevated systemic vascular in Erythromelalgia (I73.81: resistance) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Erythromelalgia: Urine Albumin-to-Creatinine Ratio [Erythromelalgia I73.81] (< 15 mg/g (I73.81)) and Home Seated Blood in Erythromelalgia (I73.81: Pressure).
Ask our AI Specialists anything about Erythromelalgia
What Is Erythromelalgia?
Recognized across U.S. clinical coding as I73.81 (Blood Pressure), Erythromelalgia is evaluated via duplex vascular ultrasonography [Erythromelalgia I73.81] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Erythromelalgia (ICD-10 I73.81) is driven by elevated systemic vascular in Erythromelalgia (I73.81: resistance); specialists in High Blood Pressure & Vascular Health monitor Home Seated Blood in Erythromelalgia (I73.81: Pressure) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Erythromelalgia (I73.81): calf cramping or in Erythromelalgia (I73.81: claudication triggered by)
- • Secondary Erythromelalgia clinical sign: localized extremity swelling, in Erythromelalgia (I73.81: warmth, or venous)
- • Symptom flares in Erythromelalgia correlating with Urine Albumin-to-Creatinine Ratio [Erythromelalgia I73.81] deviation outside < 15 mg/g (I73.81)
- • Functional blood pressure impact requiring duplex vascular ultrasonography [Erythromelalgia I73.81] evaluation (I73.81)
Erythromelalgia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I73.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Erythromelalgia I73.81] | < 15 mg/g (I73.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Erythromelalgia (I73.81: Pressure) | < 120/75 mmHg (I73.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Erythromelalgia I73.81] | 1.00 – 1.30 (I73.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Erythromelalgia
Treatment selection for Erythromelalgia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Erythromelalgia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A randomized, gold-standard blind study to evaluate the real-world benefits and: What a 324-Participant Study Found In Asian patients with high blood pressure, T80/A5 single-pill combination provided improved BP reduction after 8 weeks' treatment compared with A5 single-drug treatment. The Journal of international medical research • 2014-02-15 • Phase III Randomized Trial | N = 324 | 93/100 | PMID 24391142 ↗ |
| What the Latest Evidence Really Says About Comparative effectiveness and safety of statins as a class and of specific All statins showed statistically significant risk reduction of CVD and all-cause mortality in primary prevention populations while increasing the risk for some harm risks. American heart journal • 2019-04-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 30716508 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Liraglutide on heart and blood vessel Function and Myocardial Tissue Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s 2 × 10 -3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL... Journal of magnetic resonance imaging : JMRI • 2020-06-15 • Randomized Controlled Trial | N = 22 | 88/100 | PMID 31799782 ↗ |
| Can This Approach Help? Inside the Latest Research on Combined 17β-estradiol and progesterone on weight and blood pressure in Twelve-month use of E2/P4 had no clinically meaningful impact on weight or BP in postmenopausal women of the REPLENISH study. Menopause (New York, N.Y.) • 2020-09-14 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 32932401 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine of oral doses of telmisartan and nisoldipine, The results of this study strongly suggest that concomitant treatment with nisoldipine enhances telmisartan bioavailability in hypertensive individuals. Journal of clinical pharmacology • 2007-03-15 • Randomized Controlled Trial | N = 37 | 82/100 | PMID 17322141 ↗ |
Erythromelalgia Patient Community & “People Like Me” Threads
Filter Erythromelalgia community threads and patient logs by age, biological sex, dosage, and treatment duration.